login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SERES THERAPEUTICS INC (MCRB) Stock News
USA
- NASDAQ:MCRB -
US81750R2013
-
Common Stock
19.7
USD
+0.47 (+2.44%)
Last: 10/14/2025, 8:00:00 PM
19.7
USD
0 (0%)
After Hours:
10/14/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MCRB Latest News, Press Relases and Analysis
All
Press Releases
22 days ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
a month ago - By: Zacks Investment Research
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
a month ago - By: Benzinga
- Mentions:
NBY
MEIP
SMMT
TLPH
...
12 Health Care Stocks Moving In Monday's Intraday Session
a month ago - By: Benzinga
- Mentions:
MEIP
SMMT
XAIR
ISPC
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
2 months ago - By: The Motley Fool
Seres (MCRB) Q2 Loss Narrows 34%
2 months ago - By: Zacks Investment Research
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross
2 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
3 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
5 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
5 months ago - By: Zacks Investment Research
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
5 months ago - By: Yahoo Finance
- Mentions:
AAPL
CRUS
BROS
STRT
...
This Artificial Intelligence (AI) Chip Stock Is Making a Big Move, and It Has the Potential to Soar Higher
5 months ago - By: Zacks Investment Research
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
5 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
6 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
6 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
6 months ago - By: Zacks Investment Research
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
7 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
7 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
8 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
9 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
9 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
10 months ago - By: Seres Therapeutics, Inc.
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Please enable JavaScript to continue using this application.